欧洲医药保健网分类系统在间质性肺疾病医药联合门诊中的实践

Exploration of PCNE Classification System in Practice in Physician-and Pharmacist-Managed Clinic for Interstitial Lung Diseases

目的采用欧洲医药保健网(PCNE)分类系统提升间质性肺疾病医药联合门诊中药师识别与解决药物相关问题(DRPs)的能力。方法纳入2022年2月1日—2023年2月1日在华中科技大学同济医学院附属同济医院医药联合门诊的患者,采用PCNE分类系统分析DRPs类型、原因分型、干预类型、干预的接受情况和解决情况。结果纳入患者128例,共发现DRPs178个,平均每例患者1.39个DRPs。问题类型主要是有效性(127个,71.35%)和安全性(39个,21.91%);主要的原因分型:患者相关(85个,47.75%),药物选择(30个,16.85%)及剂量选择(27个,15.17%);主要干预类型:患者层面(176个,54.32%);药师为医师和患者提供243个干预措施,医师和患者接受231个,总体接受度为95.06%;最终,152个(85.39%)DRPs被解决。结论PCNE分类系统有助于提高医药联合门诊中DRPs识别和解决效率,促进药学服务模式的标准化、便捷化及精准化,提升患者用药的合理性、安全性和有效性。

Objective To promote the pharmacist's ability to identify and resolve drug-related problems(DRPs)in Physician-and pharmacist-managed clinic of interstitial lung disease using pharmaceutical care network Europe(PCNE)classification system.Methods Patients of physician-and pharmacist-managed clinic from February 1,2022 to February 1,2023 were included.Problems,causes,intervention types,intervention acceptability,and solution state of DRPs were analyzed using the PCNE classification system.Results A total of 128 patients were included and 178 DRPs were identified,with an average of 1.39 DRPs per patient.The main types of problems were effectiveness(127 cases,71.35%)and safety(39 cases,21.91%);The main causes classification were patient-related(85 cases,47.75%),drug selection(30 cases,16.85%)and dose selection(27 cases,15.17%);The main intervention type was patient-level(176 cases,54.32%).A total of 243 interventions were provided to physicians and patients by pharmacists,in which 231 interventions were accepted with the overall acceptance rate of 95.06%.Ultimately,152(85.39%)DRPs were resolved.Conclusion The PCNE classification system is helpful to improve the efficiency of DRP recognition and resolution in the joint outpatient clinic,promote the standardization,convenience,and precision of the pharmaceutical care model,and improve the rationality,safety,and effectiveness of patients'drug use.